Participant flow18

How many started, completed or left each group, period by period.

1 to 18 of 18

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	153
Overall Study	STARTED	Dupilumab 300 mg q2w Then q4w	145
Overall Study	STARTED	Dupilumab 300 mg q2w	150
Overall Study	Intent-to-Treat (ITT) Population	Placebo	153
Overall Study	Intent-to-Treat (ITT) Population	Dupilumab 300 mg q2w Then q4w	145
Overall Study	Intent-to-Treat (ITT) Population	Dupilumab 300 mg q2w	150
Overall Study	Treated	Placebo	152
Overall Study	Treated	Dupilumab 300 mg q2w Then q4w	145
Overall Study	Treated	Dupilumab 300 mg q2w	150
Overall Study	Safety Population	Placebo	150
Overall Study	Safety Population	Dupilumab 300 mg q2w Then q4w	148
Overall Study	Safety Population	Dupilumab 300 mg q2w	149
Overall Study	COMPLETED	Placebo	136
Overall Study	COMPLETED	Dupilumab 300 mg q2w Then q4w	140
Overall Study	COMPLETED	Dupilumab 300 mg q2w	144
Overall Study	NOT COMPLETED	Placebo	17
Overall Study	NOT COMPLETED	Dupilumab 300 mg q2w Then q4w	5
Overall Study	NOT COMPLETED	Dupilumab 300 mg q2w	6

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02898454/flow